Skip to main content
Journal cover image

Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer.

Publication ,  Journal Article
Liu, SV; Camidge, DR; Gettinger, SN; Giaccone, G; Heist, RS; Hodi, FS; Ready, NE; Zhang, W; Wallin, J; Funke, R; Waterkamp, D; Foster, P ...
Published in: Eur J Cancer
September 2018

BACKGROUND: Before the availability of immunotherapy, chemotherapy was standard first-line therapy for non-small-cell lung cancer (NSCLC) lacking actionable gene alterations. Preclinical evidence suggests chemotherapy is immunomodulatory, supporting chemotherapy/immunotherapy combinations. Atezolizumab, anti-programmed death ligand-1 (PD-L1) antibody, blocks programmed cell death protein-1 and B7.1 interaction with PD-L1. GP28328 (NCT01633970) assessed atezolizumab with chemotherapy in multiple tumours; we report results for advanced, treatment-naïve NSCLC. METHODS: Patients received atezolizumab plus carboplatin with paclitaxel (Arm C: atezo/cb/pac), pemetrexed (Arm D: atezo/cb/pem, maintenance pemetrexed permitted), or nab-paclitaxel (Arm E: atezo/cb/nab-pac), four-six cycles, then atezolizumab maintenance. Primary end-point was safety; secondary end-points were objective response rate (ORR), progression-free survival (PFS) and overall survival (OS). RESULTS: Seventy-six NSCLC patients were enrolled (n = 25, 25 and 26 for Arms C, D and E, respectively). Common treatment-related grade III/IV adverse events were neutropenia (36% atezo/cb/pac, 36% atezo/cb/pem, 42% atezo/cb/nab-pac) and anaemia (16% atezo/cb/pac, 16% atezo/cb/pem, 31% atezo/cb/nab-pac). Confirmed ORRs were 36% atezo/cb/pac, 68% atezo/cb/pem (one complete response [CR]) and 46% atezo/cb/nab-pac (four CRs). Median PFS was 7.1 months, (95% confidence interval [CI]: 4.2-8.3), 8.4 months (95% CI: 4.7-11) and 5.7 months (95% CI: 4.4-14.8), respectively. Median OS was 12.9 months (95% CI: 8.8-21.3), 18.9 months (95% CI: 9.9-27.4) and 17.0 months (95% CI: 12.7-not evaluable), respectively. CONCLUSION: Atezolizumab with chemotherapy was well tolerated with encouraging efficacy, though the analysis was limited by small numbers. NSCLC chemotherapy combination studies are ongoing. CLINICALTRIALS. GOV IDENTIFIER: NCT01633970.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Eur J Cancer

DOI

EISSN

1879-0852

Publication Date

September 2018

Volume

101

Start / End Page

114 / 122

Location

England

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Survival Analysis
  • Oncology & Carcinogenesis
  • Neutropenia
  • Middle Aged
  • Male
  • Lung Neoplasms
  • Humans
  • Follow-Up Studies
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Liu, S. V., Camidge, D. R., Gettinger, S. N., Giaccone, G., Heist, R. S., Hodi, F. S., … Powderly, J. (2018). Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer. Eur J Cancer, 101, 114–122. https://doi.org/10.1016/j.ejca.2018.06.033
Liu, Stephen V., D Ross Camidge, Scott N. Gettinger, Giuseppe Giaccone, Rebecca S. Heist, F Stephen Hodi, Neal E. Ready, et al. “Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer.Eur J Cancer 101 (September 2018): 114–22. https://doi.org/10.1016/j.ejca.2018.06.033.
Liu SV, Camidge DR, Gettinger SN, Giaccone G, Heist RS, Hodi FS, et al. Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer. Eur J Cancer. 2018 Sep;101:114–22.
Liu, Stephen V., et al. “Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer.Eur J Cancer, vol. 101, Sept. 2018, pp. 114–22. Pubmed, doi:10.1016/j.ejca.2018.06.033.
Liu SV, Camidge DR, Gettinger SN, Giaccone G, Heist RS, Hodi FS, Ready NE, Zhang W, Wallin J, Funke R, Waterkamp D, Foster P, Iizuka K, Powderly J. Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer. Eur J Cancer. 2018 Sep;101:114–122.
Journal cover image

Published In

Eur J Cancer

DOI

EISSN

1879-0852

Publication Date

September 2018

Volume

101

Start / End Page

114 / 122

Location

England

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Survival Analysis
  • Oncology & Carcinogenesis
  • Neutropenia
  • Middle Aged
  • Male
  • Lung Neoplasms
  • Humans
  • Follow-Up Studies